Results 121 to 130 of about 21,570 (177)

Ninjurin1 in cardiovascular and vascular biology: From molecular mechanisms to therapeutic opportunities

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
NINJ1 mediates PMR in cardiovascular cell death, releasing DAMPs that amplify vascular inflammation. Dual NINJ1 paradox: membrane‐bound form drives endothelial NF‐κB/CXCL‐8 inflammation while soluble form provides atheroprotection. Pericyte NINJ1 regulates the critical balance between angiogenic sprouting and vessel maturation in ischaemic tissues ...
Muhammad Mamunur Rashid Mahib
wiley   +1 more source

Targeting the Nrf2/TGF‐β1/Smad Signaling Pathway: A Novel Strategy for Urolithin A to Alleviate Renal Fibrosis

Food Frontiers, Volume 7, Issue 2, March 2026.
The diagram of the mechanism of action by which UroA regulates RF. ABSTRACT The global prevalence and mortality rates associated with chronic kidney disease (CKD) have been on a continuous rise over recent decades. Renal fibrosis (RF) serves as a critical factor in the progression of CKD to end‐stage renal disease.
Xue Wu, Jiating Li, Yonghui Dong, Jia Li, Ji Bian, Chao Liu, Hongbo Zhang, Lin Han, Min Wang   +8 more
wiley   +1 more source

Ischemic core reversal on neuroimaging following endovascular reperfusion: A systematic review and meta-analysis. [PDF]

J Cereb Blood Flow Metab
Alqahtani MS, Alamri AF, Alkhiri A, Alturki F, Al Shankiti MA, Bakry SS, Aljohani A, Alqurashi S, Alotaibi FF, Asiri MA, Tamim H, Alrohimi A, Albers GW, Shuaib A, Alhazzani A, Al-Ajlan FS.   +15 more
europepmc   +1 more source

Leonurine: A Multifaceted Bioactive Alkaloid—From Pharmacological Mechanisms to Clinical Translation: A Narrative Review

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Leonurine (LEO), a bioactive alkaloid derived from the Leonurus genus, exhibits diverse pharmacological activities including uterotonic, antioxidant, anti‐inflammatory, antiapoptotic, Antitumor, and vasoprotective effects. This review aims to provide a comprehensive overview of LEO's pharmacokinetics, pharmacological mechanisms ...
Zhouyue Gu
wiley   +1 more source

Biomarkers for the estimation of isoproterenol‐induced myocardial infarction: A review of key parameters

Journal of Intelligent Medicine, Volume 3, Issue 1, Page 47-68, March 2026.
Abstract The isoproterenol‐induced myocardial infarction model is a well‐established experimental approach for studying cardiac injury and testing potential protective treatments. By overstimulating beta‐adrenergic receptors, this model closely reproduces key features of human heart attacks, including oxidative damage, calcium imbalance, inflammatory ...
Bushra Imran, Tarique Mahmood, Farogh Ahsan, Shahzadi Bano, Vaseem Ahamad Ansari, Mohd Adnan   +5 more
wiley   +1 more source

Case Report: The aslanger pattern as an indicator of severe acute coronary syndrome. [PDF]

Front Cardiovasc Med
Chen YZ, Yao ZY, Lin LW, Luo QY, Li R, Zhao XJ.   +5 more
europepmc   +1 more source

LKB1–AMPK Signaling Pathway in Cardiovascular and Other Diseases

MedComm, Volume 7, Issue 3, March 2026.
The LKB1–AMPK pathway has a central regulatory role in various diseases. Dysfunction of this pathway can lead to pathological processes in cardiovascular diseases (atrial fibrillation, myocardial infarction, myocardial hypertrophy, atherosclerosis), metabolic diseases (diabetes and kidney disease), neurodegenerative diseases (Alzheimer's disease ...
Zhuo Chen, Qin Yang, Guo‐Wei He
wiley   +1 more source

Successful reperfusion for better outcomes in medium vessel occlusion: Penumbral salvage versus infarct volume reduction. [PDF]

Eur Stroke J
He G, Yi T, Deng J, Wei L, Lu H, Lin X, Zhang Y, Miao G, Zhu Y.   +8 more
europepmc   +1 more source

The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities

MedComm, Volume 7, Issue 3, March 2026.
Diverse diseases converge on NLRP3. We depict a discovery‐to‐clinic track: high‐throughput/phenotypic screens, structure‐guided design, and modality innovation (allosteric inhibitors, interface blockers, degraders) deliver third‐generation, disease‐tailored NLRP3 control.
Chan Zou, Shilong Jiang, Hui Li, Kai Zhao, Dongshen Cao, Guoping Yang   +5 more
wiley   +1 more source

Diagnostic challenges in acute coronary syndrome: reconciling the STEMI-NSTEMI and OMI-NOMI paradigms. [PDF]

BMC Cardiovasc Disord
Umit TB, Sogut O, Arslan M, Az A, Dogan Y, Polat SN, Belen E.   +6 more
europepmc   +1 more source